Wednesday, July 8, 2026

Drug profile · INN

alprazolam

alprazolam (ALPRAX 0.5) is a gaba-a receptor; anion channel positive allosteric modulator. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.

FDA: approved TGA: approved
US status approved
Patents linked 6
Pipeline programs 11
News articles 0
Drug details — alprazolam
US status
approved
Class
Route
ORAL
Patents
6
Programs
11
Data quality
0.89

Quick answer

alprazolam (ALPRAX 0.5) is a gaba-a receptor; anion channel positive allosteric modulator. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN alprazolam
Brand ALPRAX 0.5
Mechanism GABA-A receptor; anion channel positive allosteric modulator
Target GABA-A receptor; anion channel
Route ORAL
Formulation TABLET, ORALLY DISINTEGRATING

Mechanism of action

GABA-A receptor; anion channel positive allosteric modulator

Primary target: GABA-A receptor; anion channel

Approval history

Authority Status Date
FDA approved
TGA approved

Pipeline programs

  1. ADX-102 Ophthalmic Solution (0.5%) Phase 3 · Aldeyra Therapeutics · Non-infectious Anterior Uveitis
  2. EP0162 Phase 3 · Anaxis Pharma · Stereotypical prolonged seizure
  3. EP0165 Phase 3 · Anaxis Pharma · Treatment of stereotypical prolonged seizure
  4. 0.5% Ivermectin lotion Phase 2 · United Therapeutics Europe · Pediculosis Capitis
  5. A.1 Lucinactant Phase 2 · WINDTREE THERAPEUTICS INC · Acute Respiratory Distress Syndrome
  6. ADX-102 Ophthalmic Drops (0.5%) Phase 2 · Aldeyra Therapeutics · Conjunctivitis, Allergic
  7. ADX-102 Ophthalmic Solution (0.5%) Phase 2 · Aldeyra Therapeutics · Dry Eye Syndromes
  8. Alprazolam Phase 2 · BRIGHT MINDS BIOSCIENCES · Drug Interactions

Related & competitor drugs

  1. acamprosate calcium GABA-A receptor; anion channel positive modulator
  2. butabarbital sodium GABA-A receptor; anion channel positive allosteric modulator
  3. chlordiazepoxide hydrochloride GABA-A receptor; anion channel positive allosteric modulator
  4. clobazam GABA-A receptor; anion channel positive allosteric modulator
  5. clonazepam GABA-A receptor; anion channel positive allosteric modulator
  6. clorazepate dipotassium GABA-A receptor; anion channel positive allosteric modulator
  1. WO 2009026621

    COMPOSÉ ET COMPOSITION PHARMACEUTIQUES

    Expires Wed Feb 28 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  2. CA 2677623

    FORME PHARMACEUTIQUE CONTENANT DEUX OU DAVANTAGE DE PRINCIPES ACTIFS PHARMACEUTIQUES SOUS DES FORMES PHYSIQUES DIFFERENTES

    Expires Wed Aug 09 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  3. CA 2673418

    COMPOSE ET COMPOSITION PHARMACEUTIQUES

    Expires Wed Jun 21 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  4. CA 2673419

    COMPOSITION PHARMACEUTIQUE

    Expires Wed Jun 21 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  5. CA 2653382

    COMPOSITION STABILISEE COMPRENANT DES INHIBITEURS DE L'ECA

    Expires Wed Dec 29 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  6. CA 2628716

    PROCESSUS DE REGULATION DE LA DIMENSION DE PARTICULE

    Expires Thu May 13 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is alprazolam?

alprazolam (ALPRAX 0.5) is a gaba-a receptor; anion channel positive allosteric modulator. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for alprazolam?

ALPRAX 0.5 is a marketed brand name for alprazolam. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of alprazolam?

alprazolam has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.